These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 27423391)

  • 1. Anti-PD1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis.
    Fujita K; Terashima T; Mio T
    J Thorac Oncol; 2016 Dec; 11(12):2238-2240. PubMed ID: 27423391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
    La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
    Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer.
    Tanvetyanon T; Creelan BC; Antonia SJ
    Expert Rev Anticancer Ther; 2016 Sep; 16(9):903-10. PubMed ID: 27488231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.
    Giroux Leprieur E; Dumenil C; Julie C; Giraud V; Dumoulin J; Labrune S; Chinet T
    Eur J Cancer; 2017 Jun; 78():16-23. PubMed ID: 28407528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anti-PD1 immunotherapy followed by tuberculosis infection or reactivation].
    Viatgé T; Mazières J; Zahi S; Fajadet P; Pétureau F
    Rev Mal Respir; 2020 Sep; 37(7):595-601. PubMed ID: 32636051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety of nivolumab for the treatment of advanced non-small cell lung cancer.
    Metro G; Ricciuti B; Brambilla M; Baglivo S; Soli I; Minenza E; Leonardi GC; D'arpino A; Colabrese D; Tazza M; Zicari D; Minotti V; Chiari R
    Expert Opin Drug Saf; 2017 Jan; 16(1):101-109. PubMed ID: 27910704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer.
    Decatris MP; O'Byrne KJ
    Future Oncol; 2016 Aug; 12(15):1805-22. PubMed ID: 27267211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of immune checkpoint inhibitors].
    Kitano S
    Rinsho Ketsueki; 2017; 58(8):966-976. PubMed ID: 28883282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nivolumab: a review in advanced squamous non-small cell lung cancer.
    Keating GM
    Drugs; 2015 Nov; 75(16):1925-34. PubMed ID: 26514815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-related Neurological Symptoms in an Adolescent Patient Receiving the Checkpoint Inhibitor Nivolumab.
    Tchapyjnikov D; Borst AJ
    J Immunother; 2017 Sep; 40(7):286-288. PubMed ID: 28604555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Not Available].
    Mateus C; Libenciuc C; Robert C
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis.
    Bergqvist V; Hertervig E; Gedeon P; Kopljar M; Griph H; Kinhult S; Carneiro A; Marsal J
    Cancer Immunol Immunother; 2017 May; 66(5):581-592. PubMed ID: 28204866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute Cerebellar Ataxia Induced by Nivolumab.
    Kawamura R; Nagata E; Mukai M; Ohnuki Y; Matsuzaki T; Ohiwa K; Nakagawa T; Kohno M; Masuda R; Iwazaki M; Takizawa S
    Intern Med; 2017; 56(24):3357-3359. PubMed ID: 29249765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab: targeting PD-1 to bolster antitumor immunity.
    Brahmer JR; Hammers H; Lipson EJ
    Future Oncol; 2015; 11(9):1307-26. PubMed ID: 25798726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma.
    Okano Y; Satoh T; Horiguchi K; Toyoda M; Osaki A; Matsumoto S; Tomaru T; Nakajima Y; Ishii S; Ozawa A; Shibusawa N; Shimada T; Higuchi T; Chikamatsu K; Yamada M
    Endocr J; 2016 Oct; 63(10):905-912. PubMed ID: 27440480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immune-related adverse events by immune checkpoint inhibitors].
    Kadono T
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):83-89. PubMed ID: 28603205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunotherapy in non-small cell lung cancer: inhibition of PD1/PDL1 pathway].
    Guilleminault L; Carmier D; Heuzé-Vourc'h N; Diot P; Pichon E
    Rev Pneumol Clin; 2015 Feb; 71(1):44-56. PubMed ID: 25687821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary sarcoid-like granulomatosis induced by nivolumab.
    Montaudié H; Pradelli J; Passeron T; Lacour JP; Leroy S
    Br J Dermatol; 2017 Apr; 176(4):1060-1063. PubMed ID: 27291635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
    Rizvi NA; Mazières J; Planchard D; Stinchcombe TE; Dy GK; Antonia SJ; Horn L; Lena H; Minenza E; Mennecier B; Otterson GA; Campos LT; Gandara DR; Levy BP; Nair SG; Zalcman G; Wolf J; Souquet PJ; Baldini E; Cappuzzo F; Chouaid C; Dowlati A; Sanborn R; Lopez-Chavez A; Grohe C; Huber RM; Harbison CT; Baudelet C; Lestini BJ; Ramalingam SS
    Lancet Oncol; 2015 Mar; 16(3):257-65. PubMed ID: 25704439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immune-related adverse events of immune checkpoint inhibitors].
    Tadano H; Torigoe T
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):102-108. PubMed ID: 28603200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.